Browse > Article
http://dx.doi.org/10.5483/BMBRep.2013.46.3.036

Impact of tumour associated macrophages in pancreatic cancer  

Mielgo, Ainhoa (Liverpool Cancer Research UK Centre, Department of Molecular and Clinical Cancer Medicine, University of Liverpool)
Schmid, Michael C. (Liverpool Cancer Research UK Centre, Department of Molecular and Clinical Cancer Medicine, University of Liverpool)
Publication Information
BMB Reports / v.46, no.3, 2013 , pp. 131-138 More about this Journal
Abstract
During cancer progression, bone marrow derived myeloid cells, including immature myeloid cells and macrophages, progressively accumulate at the primary tumour site where they contribute to the establishment of a tumour promoting microenvironment. A marked infiltration of macrophages into the stromal compartment and the generation of a desmoplastic stromal reaction is a particular characteristic of pancreatic ductal adenocarcinoma (PDA) and is thought to play a key role in disease progression and its response to therapy. Tumour associated macrophages (TAMs) foster PDA tumour progression by promoting angiogenesis, metastasis, and by suppressing an anti-tumourigenic immune response. Recent work also suggests that TAMs contribute to resistance to chemotherapy and to the emergence of cancer stem-like cells. Here we will review the current understanding of the biology and the pro-tumourigenic functions of TAMs in cancer and specifically in PDA, and highlight potential therapeutic strategies to target TAMs and to improve current therapies for pancreatic cancer.
Keywords
Cancer; Macrophage; Myeloid cells; Pancreatic ductal adenocarcinoma; Tumour microenvironment;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Conroy, T., Desseigne, F., Ychou, M., Bouche, O., Guimbaud, R., Becouarn, Y., Adenis, A., Raoul, J. L., Gourgou-Bourgade, S., de la Fouchardiere, C., Bennouna, J., Bachet, J. B., Khemissa-Akouz, F., Pere-Verge, D., Delbaldo, C., Assenat, E., Chauffert, B., Michel, P., Montoto-Grillot, C. and Ducreux, M. (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364, 1817-1825.   DOI   ScienceOn
2 Neoptolemos, J. P. (2011) Adjuvant treatment of pancreatic cancer. Eur. J. Cancer 47(Suppl 3), S378-380.
3 Erkan, M., Hausmann, S., Michalski, C. W., Fingerle, A. A., Dobritz, M., Kleeff, J. and Friess, H. (2012) The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. Nat. Rev. Gastroenterol. Hepatol. 9, 454-467.   DOI
4 Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., Frese, K. K., Denicola, G., Feig, C., Combs, C., Winter, S. P., Ireland-Zecchini, H., Reichelt, S., Howat, W. J., Chang, A., Dhara, M., Wang, L., Ruckert, F., Grutzmann, R., Pilarsky, C., Izeradjene, K., Hingorani, S. R., Huang, P., Davies, S. E., Plunkett, W., Egorin, M., Hruban, R. H., Whitebread, N., McGovern, K., Adams, J., Iacobuzio-Donahue, C., Griffiths, J. and Tuveson, D. A. (2009) Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324, 1457-1461.   DOI   ScienceOn
5 Erez, N., Truitt, M., Olson, P., Arron, S. T. and Hanahan, D. (2010) Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-Dependent manner. Cancer Cell 17, 135-147.   DOI   ScienceOn
6 Beatty, G. L., Chiorean, E. G., Fishman, M. P., Saboury, B., Teitelbaum, U. R., Sun, W., Huhn, R. D., Song, W., Li, D., Sharp, L. L., Torigian, D. A., O'Dwyer, P. J. and Vonderheide, R. H. (2011) CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331, 1612-1616.   DOI   ScienceOn
7 Biswas, S. K. and Mantovani, A. (2010) Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 11, 889-896.   DOI   ScienceOn
8 Hildenbrand, R., Dilger, I., Horlin, A. and Stutte, H. J. (1995) Urokinase and macrophages in tumour angiogenesis. Br. J. Cancer 72, 818-823.   DOI   ScienceOn
9 Olson, P., Chu, G. C., Perry, S. R., Nolan-Stevaux, O. and Hanahan, D. (2011) Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma. Proc. Natl. Acad. Sci. U.S.A. 108, E1275-1284.   DOI
10 Vincent, A., Herman, J., Schulick, R., Hruban, R. H. and Goggins, M. (2011) Pancreatic cancer. Lancet 378, 607-620.   DOI   ScienceOn
11 Schmid, M. C., Avraamides, C. J., Dippold, H. C., Franco, I., Foubert, P., Ellies, L. G., Acevedo, L. M., Manglicmot, J. R., Song, X., Wrasidlo, W., Blair, S. L., Ginsberg, M. H., Cheresh, D. A., Hirsch, E., Field, S. J. and Varner, J. A. (2011) Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kgamma, a single convergent point promoting tumor inflammation and progression. Cancer Cell 19, 715-727.   DOI   ScienceOn
12 Schmid, M. C., Avraamides, C. J., Foubert, P., Shaked, Y., Kang, S. W., Kerbel, R. S. and Varner, J. A. (2011) Combined blockade of integrin-alpha4beta1 plus cytokines SDF-1alpha or IL-1beta potently inhibits tumor inflammation and growth. Cancer Res 71, 6965-6975.   DOI   ScienceOn
13 Tugues, S., Honjo, S., Konig, C., Noguer, O., Hedlund, M., Botling, J., Deschoemaeker, S., Wenes, M., Rolny, C., Jahnen-Dechent, W., Mazzone, M. and Claesson-Welsh, L. (2012) Genetic deficiency in plasma protein HRG enhances tumor growth and metastasis by exacerbating immune escape and vessel abnormalization. Cancer Res. 72, 1953-1963.   DOI   ScienceOn
14 Mazzieri, R., Pucci, F., Moi, D., Zonari, E., Ranghetti, A., Berti, A., Politi, L. S., Gentner, B., Brown, J. L., Naldini, L. and De Palma, M. (2011) Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 19, 512-526.   DOI   ScienceOn
15 Joyce, J. A. and Pollard, J. W. (2009) Microenvironmental regulation of metastasis. Nat. Rev. Cancer 9, 239-252.   DOI   ScienceOn
16 Stokes, J. B., Adair, S. J., Slack-Davis, J. K., Walters, D. M., Tilghman, R. W., Hershey, E. D., Lowrey, B., Thomas, K. S., Bouton, A. H., Hwang, R. F., Stelow, E. B., Parsons, J. T. and Bauer, T. W. (2011) Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment. Mol. Cancer Ther. 10, 2135-2145.   DOI
17 Kleeff, J., Kusama, T., Rossi, D. L., Ishiwata, T., Maruyama, H., Friess, H., Buchler, M. W., Zlotnik, A. and Korc, M. (1999) Detection and localization of Mip-3alpha/LARC/Exodus, a macrophage proinflammatory chemokine, and its CCR6 receptor in human pancreatic cancer. Int. J. Cancer 81, 650-657.   DOI
18 Campbell, A. S., Albo, D., Kimsey, T. F., White, S. L. and Wang, T. N. (2005) Macrophage inflammatory protein-3alpha promotes pancreatic cancer cell invasion. J. Surg. Res. 123, 96-101.   DOI   ScienceOn
19 Kimsey, T. F., Campbell, A. S., Albo, D., Wilson, M. and Wang, T. N. (2004) Co-localization of macrophage inflammatory protein-3alpha (Mip-3alpha) and its receptor, CCR6, promotes pancreatic cancer cell invasion. Cancer J. 10, 374-380.   DOI
20 Cavel, O., Shomron, O., Shabtay, A., Vital, J., Trejo-Leider, L., Weizman, N., Krelin, Y., Fong, Y., Wong, R. J., Amit, M. and Gil, Z. (2012) Endoneurial macrophages induce perineural invasion of pancreatic cancer cells by secretion of GDNF and activation of RET tyrosine kinase receptor. Cancer Res. 72, 5733-5743.   DOI   ScienceOn
21 Schoppmann, S. F., Fenzl, A., Nagy, K., Unger, S., Bayer, G., Geleff, S., Gnant, M., Horvat, R., Jakesz, R. and Birner, P. (2006) VEGF-C expressing tumor-associated macrophages in lymph node positive breast cancer: impact on lymphangiogenesis and survival. Surgery 139, 839-846.   DOI   ScienceOn
22 Zumsteg, A., Baeriswyl, V., Imaizumi, N., Schwendener, R., Ruegg, C. and Christofori, G. (2009) Myeloid cells contribute to tumor lymphangiogenesis. PLoS One 4, e7067.   DOI   ScienceOn
23 Ruffell, B., Au, A., Rugo, H. S., Esserman, L. J., Hwang, E. S. and Coussens, L. M. (2012) Leukocyte composition of human breast cancer. Proc. Natl. Acad. Sci. U.S.A. 109, 2796-2801.   DOI
24 Kurahara, H., Shinchi, H., Mataki, Y., Maemura, K., Noma, H., Kubo, F., Sakoda, M., Ueno, S., Natsugoe, S. and Takao, S. (2011) Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. J. Surg. Res. 167, e211-219.   DOI   ScienceOn
25 Kurahara, H., Takao, S., Maemura, K., Mataki, Y., Kuwahata, T., Maeda, K., Sakoda, M., Iino, S., Ishigami, S., Ueno, S., Shinchi, H. and Natsugoe, S. (2013) M2-Polarized tumor-associated macrophage infiltration of regional lymph nodes is associated with nodal lymphangiogenesis and occult nodal involvement in pN0 pancreatic cancer. Pancreas 42, 155-159.   DOI   ScienceOn
26 Jinushi, M., Chiba, S., Yoshiyama, H., Masutomi, K., Kinoshita, I., Dosaka-Akita, H., Yagita, H., Takaoka, A. and Tahara, H. (2011) Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells. Proc. Natl. Acad. Sci. U.S.A. 108, 12425-12430.   DOI   ScienceOn
27 Greten, F. R., Eckmann, L., Greten, T. F., Park, J. M., Li, Z. W., Egan, L. J., Kagnoff, M. F. and Karin, M. (2004) IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118, 285-296.   DOI   ScienceOn
28 Karp, C. L. and Murray, P. J. (2012) Non-canonical alternatives: what a macrophage is 4. J. Exp. Med. 209, 427-431.   DOI
29 Gordon, S. and Martinez, F. O. (2010) Alternative activation of macrophages: mechanism and functions. Immunity 32, 593-604.   DOI   ScienceOn
30 Mantovani, A. and Sica, A. (2010) Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr. Opin. Immunol. 22, 231-237.   DOI   ScienceOn
31 Karin, M. and Greten, F. R. (2005) NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 5, 749-759.   DOI   ScienceOn
32 Lin, E. Y., Li, J. F., Gnatovskiy, L., Deng, Y., Zhu, L., Grzesik, D. A., Qian, H., Xue, X. N. and Pollard, J. W. (2006) Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res. 66, 11238-11246.   DOI   ScienceOn
33 Qian, B., Deng, Y., Im, J. H., Muschel, R. J., Zou, Y., Li, J., Lang, R. A. and Pollard, J. W. (2009) A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS One 4, e6562.   DOI   ScienceOn
34 Ruffell, B., Affara, N. I. and Coussens, L. M. (2012) Differential macrophage programming in the tumor microenvironment. Trends Immunol. 33, 119-126.   DOI   ScienceOn
35 Yoshikawa, K., Mitsunaga, S., Kinoshita, T., Konishi, M., Takahashi, S., Gotohda, N., Kato, Y., Aizawa, M. and Ochiai, A. (2012) Impact of tumor-associated macrophages on invasive ductal carcinoma of the pancreas head. Cancer Sci. 103, 2012-2020.   DOI   ScienceOn
36 Perides, G., Weiss, E. R., Michael, E. S., Laukkarinen, J. M., Duffield, J. S. and Steer, M. L. (2011) TNF-alpha-dependent regulation of acute pancreatitis severity by Ly-6C(hi) monocytes in mice. J. Biol. Chem. 286, 13327-13335.   DOI   ScienceOn
37 Sah, R. P. and Chari, S. T. (2012) Autoimmune pancreatitis: an update on classification, diagnosis, natural history and management. Curr. Gastroenterol. Rep. 14, 95-105.   DOI   ScienceOn
38 Sah, R. P., Garg, P. and Saluja, A. K. (2012) Pathogenic mechanisms of acute pancreatitis. Curr. Opin. Gastroenterol. 28, 507-515.   DOI
39 Dugernier, T. L., Laterre, P. F., Wittebole, X., Roeseler, J., Latinne, D., Reynaert, M. S. and Pugin, J. (2003) Compartmentalization of the inflammatory response during acute pancreatitis: correlation with local and systemic complications. Am. J. Respir. Crit. Care Med. 168, 148-157.   DOI   ScienceOn
40 Sendler, M., Dummer, A., Weiss, F. U., Kruger, B., Wartmann, T., Scharffetter-Kochanek, K., van Rooijen, N., Malla, S. R., Aghdassi, A., Halangk, W., Lerch, M. M. and Mayerle, J. (2013) Tumour necrosis factor alpha secretion induces protease activation and acinar cell necrosis in acute experimental pancreatitis in mice. Gut. 62, 430-439.   DOI   ScienceOn
41 Infante, J. R., Matsubayashi, H., Sato, N., Tonascia, J., Klein, A. P., Riall, T. A., Yeo, C., Iacobuzio-Donahue, C. and Goggins, M. (2007) Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J. Clin. Oncol. 25, 319-325.   DOI   ScienceOn
42 Arnold, S. A., Rivera, L. B., Miller, A. F., Carbon, J. G., Dineen, S. P., Xie, Y., Castrillon, D. H., Sage, E. H., Puolakkainen, P., Bradshaw, A. D. and Brekken, R. A. (2010) Lack of host SPARC enhances vascular function and tumor spread in an orthotopic murine model of pancreatic carcinoma. Dis. Model Mech. 3, 57-72.   DOI
43 Gabrilovich, D. I., Ostrand-Rosenberg, S. and Bronte, V. (2012) Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12, 253-268.   DOI   ScienceOn
44 Desai, N., Trieu, V., Yao, Z., Louie, L., Ci, S., Yang, A., Tao, C., De, T., Beals, B., Dykes, D., Noker, P., Yao, R., Labao, E., Hawkins, M. and Soon-Shiong, P. (2006) Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin. Cancer Res. 12, 1317-1324.   DOI   ScienceOn
45 Von Hoff, D. D., Ramanathan, R. K., Borad, M. J., Laheru, D. A., Smith, L. S., Wood, T. E., Korn, R. L., Desai, N., Trieu, V., Iglesias, J. L., Zhang, H., Soon-Shiong, P., Shi, T., Rajeshkumar, N. V., Maitra, A. and Hidalgo, M. (2011) Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J. Clin. Oncol. 29, 4548-4554.   DOI
46 Rolny, C., Mazzone, M., Tugues, S., Laoui, D., Johansson, I., Coulon, C., Squadrito, M. L., Segura, I., Li, X., Knevels, E., Costa, S., Vinckier, S., Dresselaer, T., Akerud, P., De Mol, M., Salomaki, H., Phillipson, M., Wyns, S., Larsson, E., Buysschaert, I., Botling, J., Himmelreich, U., Van Ginderachter, J. A., De Palma, M., Dewerchin, M., Claesson-Welsh, L. and Carmeliet, P. (2011) HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through down-regulation of PlGF. Cancer Cell 19, 31-44.   DOI   ScienceOn
47 Kuang, D. M., Zhao, Q., Peng, C., Xu, J., Zhang, J. P., Wu, C. and Zheng, L. (2009) Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J. Exp. Med. 206, 1327-1337.   DOI   ScienceOn
48 Kryczek, I., Zou, L., Rodriguez, P., Zhu, G., Wei, S., Mottram, P., Brumlik, M., Cheng, P., Curiel, T., Myers, L., Lackner, A., Alvarez, X., Ochoa, A., Chen, L. and Zou, W. (2006) B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J. Exp. Med. 203, 871-881.   DOI   ScienceOn
49 Mitchem, J. B., Brennan, D. J., Knolhoff, B. L., Belt, B. A., Zhu, Y., Sanford, D. E., Belaygorod, L., Carpenter, D., Collins, L., Piwnica-Worms, D., Hewitt, S. M., Mallya Udupi, G., Gallagher, W. M., Wegner, C., West, B. L., Wang-Gillam, A., Goedegebuure, P., Linehan, D. C. and Denardo, D. G. (2013) Targeting tumor-infiltrating macrophages decreases tumor-Initiating cells, relieves immunosuppression and improves chemotherapeutic response. Cancer Res. 73, 1128-1141.   DOI   ScienceOn
50 Squadrito, M. L., Pucci, F., Magri, L., Moi, D., Gilfillan, G., Ranghetti, A., Casazza, A., Mazzone, M., Lyle, R., Naldini, L. and De Palma, M. (2012) miR-511-3p Modulates Gentic Programs of Tumor-Associated Macrophages. Cell Rep. 1, 141-154.   DOI   ScienceOn
51 Bayne, L. J., Beatty, G. L., Jhala, N., Clark, C. E., Rhim, A. D., Stanger, B. Z. and Vonderheide, R. H. (2012) Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 21, 822-835.   DOI   ScienceOn
52 Narita, Y., Wakita, D., Ohkur, T., Chamoto, K. and Nishimura, T. (2009) Potential differentiation of tumor bearing mouse CD11b+Gr-1+ immature myeloid cells into both suppressor macrophages and immunostimulatory dendritic cells. Biomed. Res. 30, 7-15.   DOI
53 Kusmartsev, S., Nagaraj, S. and Gabrilovich, D. I. (2005) Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells. J. Immunol. 175, 4583-4592.   DOI
54 Lewis, J. S., Landers, R. J., Underwood, J. C., Harris, A. L. and Lewis, C. E. (2000) Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas. J. Pathol. 192, 150-158.   DOI
55 Sunderkotter, C., Steinbrink, K., Goebeler, M., Bhardwaj, R. and Sorg, C. (1994) Macrophages and angiogenesis. J. Leukoc. Biol. 55, 410-422.
56 Giraudo, E., Inoue, M. and Hanahan, D. (2004) An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J. Clin. Invest. 114, 623-633.   DOI   ScienceOn
57 Ojajarvi, I. A., Partanen, T. J., Ahlbom, A., Boffetta, P., Hakulinen, T., Jourenkova, N., Kauppinen, T. P., Kogevinas, M., Porta, M., Vainio, H. U., Weiderpass, E. and Wesseling, C. H. (2000) Occupational exposures and pancreatic cancer: a meta-analysis. Occup. Environ. Med. 57, 316-324.   DOI   ScienceOn
58 Raimondi, S., Maisonneuve, P. and Lowenfels, A. B. (2009) Epidemiology of pancreatic cancer: an overview. Nat. Rev. Gastroenterol. Hepatol. 6, 699-708.   DOI   ScienceOn
59 Brune, K. A., Lau, B., Palmisano, E., Canto, M., Goggins, M. G., Hruban, R. H. and Klein, A. P. (2010) Importance of age of onset in pancreatic cancer kindreds. J. Natl. Cancer Inst. 102, 119-126.   DOI   ScienceOn
60 Wolpin, B. M., Chan, A. T., Hartge, P., Chanock, S. J., Kraft, P., Hunter, D. J., Giovannucci, E. L. and Fuchs, C. S. (2009) ABO blood group and the risk of pancreatic cancer. J. Natl. Cancer Inst. 101, 424-431.   DOI   ScienceOn
61 Winter, J. M., Brennan, M. F., Tang, L. H., D'Angelica, M. I., Dematteo, R. P., Fong, Y., Klimstra, D. S., Jarnagin, W. R. and Allen, P. J. (2012) Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades. Ann. Surg. Oncol. 19, 169-175.   DOI   ScienceOn
62 Burris, H. A., 3rd, Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P., Nelson, R., Dorr, F. A., Stephens, C. D. and Von Hoff, D. D. (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 15, 2403-2413.